WallStreetZenWallStreetZen

NASDAQ: AVTE
Aerovate Therapeutics Inc Stock

$24.51+0.12 (+0.49%)
Updated Feb 3, 2023
AVTE Price
$24.51
Fair Value Price
N/A
Market Cap
$603.07M
52 Week Low
$8.33
52 Week High
$30.79
P/E
-15.61x
P/B
4.33x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$44.71M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.06
Operating Cash Flow
-$37M
Beta
1.41
Next Earnings
Mar 29, 2023
Ex-Dividend
N/A
Next Dividend
N/A

AVTE Overview

Aerovate Therapeutics Inc. is a clinical-stage biopharmaceutical company developing drugs to treat rare cardiopulmonary diseases. Pulmonary Arterial Hypertension is a rare progressive and often fatal cardiopulmonary disease affecting both the heart and lungs. Aerovate's lead program, AV-101, is an inhalable dry to address the underlying hyperproliferation of cells within the narrowed arteries of the lungs. Aerovate Therapeutics was incorporated in 2018 and is headquartered in Waltham, MA.

Zen Score

Industry Average (28)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how AVTE scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

AVTE is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
AVTE is good value based on its book value relative to its share price (4.33x), compared to the US Biotechnology industry average (5.11x)
P/B vs Industry Valuation
AVTE is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more AVTE due diligence checks available for Premium users.

Be the first to know about important AVTE news, forecast changes, insider trades & much more!

AVTE News

Valuation

AVTE fair value

Fair Value of AVTE stock based on Discounted Cash Flow (DCF)
Price
$24.51
Fair Value
$24.00
Overvalued by
2.14%
AVTE is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

AVTE price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-15.61x
Industry
10.7x
Market
15.09x

AVTE price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
4.33x
Industry
5.11x
AVTE is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

AVTE's financial health

Profit margin

Revenue
$0.0
Net Income
-$13.6M
Profit Margin
0%
AVTE's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$147.7M
Liabilities
$8.5M
Debt to equity
0.06
AVTE's short-term assets ($145.16M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
AVTE's short-term assets ($145.16M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
AVTE's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$9.7M
Investing
$4.6M
Financing
$37.0k
AVTE's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

AVTE vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
AVTE$603.07M+0.49%-15.61x4.33x
ALVR$605.56M-2.26%-2.32x2.39x
ZYME$597.21M+2.49%-2.61x3.32x
ALLK$614.32M-4.76%-1.06x1.78x
NRIX$590.29M-5.58%-3.37x1.72x

Aerovate Therapeutics Stock FAQ

What is Aerovate Therapeutics's quote symbol?

NASDAQ: AVTE) Aerovate Therapeutics trades on the NASDAQ under the ticker symbol AVTE. Aerovate Therapeutics stock quotes can also be displayed as NASDAQ: AVTE.

If you're new to stock investing, here's how to buy Aerovate Therapeutics stock.

What is the 52 week high and low for Aerovate Therapeutics (NASDAQ: AVTE)?

(NASDAQ: AVTE) Aerovate Therapeutics's 52-week high was $30.79, and its 52-week low was $8.33. It is currently -20.4% from its 52-week high and 194.24% from its 52-week low.

How much is Aerovate Therapeutics stock worth today?

(NASDAQ: AVTE) Aerovate Therapeutics currently has 24,605,073 outstanding shares. With Aerovate Therapeutics stock trading at $24.51 per share, the total value of Aerovate Therapeutics stock (market capitalization) is $603.07M.

Aerovate Therapeutics stock was originally listed at a price of $22.83 in Jun 30, 2021. If you had invested in Aerovate Therapeutics stock at $22.83, your return over the last 1 years would have been 7.36%, for an annualized return of 7.36% (not including any dividends or dividend reinvestments).

How much is Aerovate Therapeutics's stock price per share?

(NASDAQ: AVTE) Aerovate Therapeutics stock price per share is $24.51 today (as of Feb 3, 2023).

What is Aerovate Therapeutics's Market Cap?

(NASDAQ: AVTE) Aerovate Therapeutics's market cap is $603.07M, as of Feb 7, 2023.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Aerovate Therapeutics's market cap is calculated by multiplying AVTE's current stock price of $24.51 by AVTE's total outstanding shares of 24,605,073.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.